How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?   

The patient did not receive immunotherapy initially due to delayed insurance authorization. His performance status is poor, and his main toxicity from tepotinib was grade 3 edema.

Would you recommend surveillance off therapy, chemo-immunotherapy, immunotherapy alone, capmatinib, or crizotinib (given its potentially different toxicity profile)?